A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
99mTc-MIP-1404 is a radioactive diagnostic imaging agent indicated for imaging men with
newly diagnosed prostate cancer whose biopsy indicates a histopathologic Gleason Score of ≤
3+4 severity who are candidates for active surveillance and are undergoing voluntary radical
prostatectomy (RP) [Cohort A] or routine prostate biopsy [Cohort B]. This Phase 3 study is
designed to evaluate the specificity and sensitivity of 99mTc-MIP-1404 SPECT/CT imaging to
correctly identify subjects with previously unknown clinically significant prostate cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society